Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Valeriy V Lyzogubov, MD PhD, Pingping Qu, Cody Ashby, PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2018-99-117067

Published: 2018

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

The Mutational Landscape of Primary Plasma Cell Leukemia

Carolina D. Schinke, MD, Cody Ashby, PhD, Yan Wang, Ruslana G. Tytarenko, MS, Eileen Boyle, Christopher Wardell, PhD, Pingping Qu, Sharmilan Thanendrarajan, MD, Sandra Susanibar, MD, Naveen Yarlagadda, MD, Maliha Khan, Meera Mohan, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Bart Barlogie, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 114.

https://doi.org/10.1182/blood-2018-99-116758

Published: 2018

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Sandra Susanibar, MD, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, MD, Jorge Jo Kamimoto, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Nathan Petty, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD, Daisy Alapat, MD, Barlogie Bart, Gareth J. Morgan, MD PhD, Carolina D. Schinke, MD

Blood (2017) 130 (Supplement 1): 3047.

https://doi.org/10.1182/blood.V130.Suppl_1.3047.3047

Published: 2017

Journal Articles

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Christopher P. Wardell, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2017) 130 (Supplement 1): 1790.

https://doi.org/10.1182/blood.V130.Suppl_1.1790.1790

Published: 2017

Journal Articles

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Shmuel Yaccoby, PhD, Pingping Qu, PhD, Syed Mehdi, Antje Hoering, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 2065.

https://doi.org/10.1182/blood.V128.22.2065.2065

Published: 2016

Journal Articles

Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma

Erming Tian, PhD, Joshua Epstein, DSc, Pingping Qu, PhD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Antje Hoering, Jeffery Sawyer, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 2982.

https://doi.org/10.1182/blood.V126.23.2982.2982

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Shmuel Yaccoby, Joshua Epstein, DSc, Pingping Qu, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Faith E Davies, MD, Alan Mitchell, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1808.

https://doi.org/10.1182/blood.V126.23.1808.1808

Published: 2015

Journal Articles

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Sarah Waheed, MD, Hongwei Wang, Pingping Qu, PhD, Christoph Heuck, MD, Aasiya Matin, Yogesh Jethava, MB, MRCP, MD FRCPath, Frits van Rhee, MD PhD, Antje Hoering, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1777.

https://doi.org/10.1182/blood.V126.23.1777.1777

Published: 2015

Journal Articles

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Caleb K Stein, MS, Pingping Qu, PhD, Joshua Epstein, DSc, Adam Rosenthal, Rachel Hunter-Merrill, Ryan Williams, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3355.

https://doi.org/10.1182/blood.V124.21.3355.3355

Published: 2014

Journal Articles

Defining Risk of MGUS and AMM Progression to Myeloma By Ig Heavy-Chain FISH

Erming Tian, PhD, Pingping Qu, PhD, Caleb K Stein, MS, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2014) 124 (21): 3408.

https://doi.org/10.1182/blood.V124.21.3408.3408

Published: 2014

Journal Articles

CYR61 /CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease

Sarah K. Johnson, James P. Stewart, Rakesh Bam, Pingping Qu, Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Jr, Joshua Epstein, Shmuel Yaccoby

Blood (2014) 124 (13): 2051–2060.

https://doi.org/10.1182/blood-2014-02-555813

Published: 2014

Includes: Supplemental data

Journal Articles

Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation

Qing Zhang, Phd, Christoph Heuck, MD, Pingping Qu, PhD, Saad Z Usmani, MD, FACP, Ryan Williams, Yiming Zhou, PhD, Clyde Bailey, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1865.

https://doi.org/10.1182/blood.V122.21.1865.1865

Published: 2013

Journal Articles

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Christoph Heuck, MD, Pingping Qu, PhD, Emily Hansen, MS, Qing Zhang, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Shebli Atrash, MD, Purvi Patel, Antje Hoering, PhD, Joshua Epstein, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1913.

https://doi.org/10.1182/blood.V122.21.1913.1913

Published: 2013

Journal Articles

Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma

Christoph Heuck, MD, Pingping Qu, PhD, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD, FACP, Joshua Epstein, DSc, Qing Zhang, PhD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 125.

https://doi.org/10.1182/blood.V122.21.125.125

Published: 2013

Journal Articles

High CCN1 Levels Are Associated with Longer Progression-Free and Overall Survival in GEP-Defined High-Risk Myeloma

Sarah K. Johnson, PhD, Pingping Qu, PhD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2012) 120 (21): 3940.

https://doi.org/10.1182/blood.V120.21.3940.3940

Published: 2012

Journal Articles

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Donald Johann, MD, MS, Pingping Qu, PhD, Rachael Sexton, Antje Hoering, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Frits van Rhee, MD, PhD, Saad Z Usmani, MD FACP, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 3953.

https://doi.org/10.1182/blood.V120.21.3953.3953

Published: 2012

NARROW

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

The Mutational Landscape of Primary Plasma Cell Leukemia

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Defining Risk of MGUS and AMM Progression to Myeloma By Ig Heavy-Chain FISH

CYR61 /CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease

Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma

High CCN1 Levels Are Associated with Longer Progression-Free and Overall Survival in GEP-Defined High-Risk Myeloma

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only